🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

Increased level of Oct-1 protein in tumor cells modulates cellular response to anticancer drugs


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The effect of overexpression of Oct-1 protein isoforms on the cell response to two anticancer drugs camptothecin and dexamethasone was studied. The effect of Oct-1 isoforms on regulated gene transcription was estimated by the difference in the level of mRNA in Burkitt’s lymphoma cells (Namalwa line) untransfected and stably transfected with Oct-1 isoforms. The response to anticancer drugs of the Oct-1 target genes involved in the development of apoptosis depended, firstly, on the type of drug, secondly, on the concentration of Oct-1 in cells. and, thirdly, on the Oct-1 isoform with which these cells were transfected.

Sobre autores

T. Portseva

Engelhardt Institute of Molecular Biology

Autor responsável pela correspondência
Email: tanjnij86@mail.ru
Rússia, ul. Vavilova 32, Moscow, 119991

E. Pankratova

Engelhardt Institute of Molecular Biology

Email: tanjnij86@mail.ru
Rússia, ul. Vavilova 32, Moscow, 119991

A. Stepchenko

Engelhardt Institute of Molecular Biology

Email: tanjnij86@mail.ru
Rússia, ul. Vavilova 32, Moscow, 119991

S. Georgieva

Engelhardt Institute of Molecular Biology

Email: tanjnij86@mail.ru
Rússia, ul. Vavilova 32, Moscow, 119991

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Ltd., 2016